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ABSTRACT

Bangalore, Deepa. M.S., Department of Social and Applied Economics, Wright State
University, 2004.
Cost Effectiveness of Treating the Metabolic Syndrome in the Uninsured in Montgomery
County.1

treating the uninsured in cases of cardiovascular emergencies has demonstrated
to be a large expense to the health care system, primarily borne by the society as they
contribute to taxes/levies that support local hospitals for indigent care. Interventions to
reduce the cardiovascular risk factors among the uninsured are expensive but have proven
to be an effective alternative to the present situation, which is to treat them only in cases
of emergencies. The metabolic syndrome (MS) poses a threat particularly to the
uninsured population because of its asymptomatic nature. Detection and treatment of MS
at its onset provides substantial clinical benefit over long periods. Economic evaluations
of such an intervention prove to be beneficial since it would improve the quality of life of
individuals with the syndrome, consequently improving productivity. Although the
expense of treating the syndrome among the uninsured has to be borne by the society, the
effectiveness generated by the cost incurred lies within the realms of what society can
afford. This paper evaluates the potential benefits of treating this small portion of the
population over long periods. It presents a universal model to evaluate cost-effectiveness
of treating the uninsured with the MS, and the model is then extrapolated to the uninsured
with MS in Montgomery County to demonstrate the effectiveness of the program. The
model compares treatment of MS in the uninsured at the onset of the syndrome versus not
treating them until an event that needs medical attention occurs.
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Introduction
M e t a b o l ic S y n d r o m e
The Metabolic Syndrome (MS) is a cluster of risk
factors that are known to increase the risk of
cardiovascular and renal diseases, and its
consequences.1 (See Appendix A) It is also known as
syndrome X, dysmetabolic syndrome, plurimetabolic
syndrome, deadly quartet, or insulin resistance
syndrome.2,3 Until recently, there was no working
definition of MS. In 1998 and 2001, the World Health
organization (WHO) and the National Cholesterol
Education Program Adult Treatment Panel III (NCEP ATP
III) respectively, provided a definition of the MS. The
WHO's definition includes diabetes/impaired glucose
tolerance with two or more of the following risk factors
- obesity, dyslipidemia, hypertension, microalbuminuria.
The NCEP ATP III, however, defines MS as a combination
of three or more of the following risk factors obesity, dyslipidemia, hyperglycemia, and hypertension.3

1

Although both these definitions acknowledge that
diabetes is a component of MS, critics argue that
diabetes is a consequence of MS rather than a component
of MS. Lack of an explicit definition for MS has created
confusion in the way the syndrome has been understood,
diagnosed, and treated. Consequently, it has been the
basis for inconsistent research about the syndrome and
its subsequent consequences4.

Pr eva len c e
A study by Lakka et al5 compared the specificity
and sensitivity of the two definitions by studying
middle aged Finnish men. Their results showed that the
WHO definition had a relatively higher sensitivity and
specificity in predicting the cardiovascular and overall
mortality associated with MS. However, for the purpose
of this research, the NCEP ATP III definition is used
since the only research showing prevalence of MS in US
adults, by Ford et al,1 uses NCEP definition. They used
data from the Third National Health and Nutrition
Examination Survey (NHANES III) and concluded that there
are about 24% of US adults with the MS. The prevalence

2

increased with age and an estimated 42% of people over
the age 60 were found to have MS. Currently, this
appears to be the only prevalence data available for the
US population.

P o p u l a t io n
The syndrome is seldom identified and treated
despite the fact that patients are exposed to high
risks.6 This problem is especially important in the
context of the uninsured due to their disconnection with
the medical system. Studies have shown that the
uninsured are at a higher risk for cardiovascular
disease and all cause mortality when compared with the
general population7. Recent studies have concluded that
intensive treatment of hypertension, cholesterol, and
diabetes provides excellent cost-effective ratios.
However, the cost-effectiveness of treating the syndrome
is not explored in the uninsured population.

Although there are many opportunities that exist to
prevent or at least reduce the incidence of the risk
factors of MS, the purpose of this study is to examine
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the effects of these risk factors assuming that the
patients already have the metabolic syndrome. In the
population we are interested in, being uninsured reduces
the chances of being diagnosed of any of these risk
factors.8,9 Recognizing the fact that the uninsured go
without being treated for the risk factors until a
serious event occurs, this study examines the effect of
Early Treatment of the uninsured. The study considers
the population between the ages of 20 and 64 assuming
that after age 64 they automatically get absorbed into
the Medicare system.

In Montgomery County, Ohio, there are about 70,642
uninsured between the ages of 18 and 6410. Considering
the age-adjusted prevalence rate for MS being 24%, we
estimated that there are about 17,500 uninsured who have
the M S .

In a report by the US Public Interest Research
Group,11 the uninsured pay 72% more than the insured for
prescription drugs. Combined with the fact that most
uninsured are the working poor (See Appendix B ) , the
high costs of health care clearly discourages them from
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following treatment regimen and also causes them to
avoid seeing their physicians. The uninsured often wait
untill their illness becomes severe which eventually
drives treatment costs up to a higher level. Usually,
these costs are recovered though cost-shifting, where
the government uses taxpayers funds to pay for
uncompensated care.

This research attempts to determine

the economic value in creating a safety net by providing
preventive care to the uninsured with metabolic
syndrome, with the intention of promoting better health.
It is found that healthy people contribute towards
higher productivity by increasing labor force
participation.12,13

T r e a t m e n t O p t io n s
Each component of MS - hypertension, dyslipidemia,
obesity, and hyperglycemia - are serious risk factors of
adverse cardiovascular and renal outcomes, including
end-stage renal disease, stroke, myocardial infarction,
and death. The presence of more than one of risk factors
in MS amplifies the cardiovascular risks through
aggression of the independent metabolic components.2,3 It
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has been demonstrated that treatment directed
specifically to the individual conditions is known to
significantly reduce the risk of serious adverse
outcomes.3 For the purpose of this study, we have chosen
three main outcomes that are most prevalent and which
can be avoided or reduced by the treatment of MS stroke, myocardial infarction (MI), and end-stage renal
disease (ESRD). Hence, the interventions to reduce the
incidence of these consequences include intense
treatment of one or more of the following - blood
pressure, serum cholesterol, and blood glucose level.2'14

It is important to treat the individual risk
factors at the onset of the syndrome. Early detection
and treatment might help in decreasing treatment costs
in later years due to reduction or slow down in the
progression of major outcomes.15 Hence, the costs
associated with Early Treatment might be offset by the
benefits an individual receives in terms of increased
life years with improved quality of life.23 The Early
Treatment option is compared with current clinical
practice, using Markov Models,16 taking into account the
associated costs and benefits of the two options.

6

M ethods
Mo d e l S t r u c t u r e

Figure 1: Progression Path of Metabolic Syndrome

Figure 1 shows a simple schematic representation
modeling the progression path of the disease. As
depicted, there are two treatment options - 'Early
Treatment', which starts as a primary prevention
approach, and 'Late Term Treatment', which starts after
an event occurs. There are three major events (Stroke,
MI, and ESRD) that are integrated into the model to
simulate the progression of MS. It is expected that

7

Early Treatment can reduce or delay the events and its
outcomes when compared to Late Term Treatment. The model
calculates the additional costs and benefits of Early
Treatment versus Late Term Treatment.

Ma r k o v Mo d e l
We developed a Markov model using DATA 4.0 (TreeAge
Software, Inc., Williamstown, Massachusetts) to evaluate
two alternatives for treating MS among the uninsured.
The Markov model's ability to incorporate time dependent
variation of risks and probabilities, and its ability to
represent repeated events, made it a favorable tool to
use in this research.

Figure 2 Shows a Markov Model built in DATA 4.0.
The model assumes that at any time, all persons in the
cohort are in a definitive state. The different states
defined for this model are: well (perfect health),
severe stroke, fatal stroke, mild stroke, fatal MI, nonfatal MI, ESRD, disability, and death. For each cycle or
stage (average amount of time spent in each state) the
model calculates the proportion of the cohort in each
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health state. The cycle time chosen for the simulation
is one year, which indicates that the Markov model
allows for only one transition between events in one
year. Hence, persons
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Figure 2: Health States and Treatment Options in the Markov Model
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having a second event within one-year period are not
accounted for in this model. For each cycle, the model
calculates, the number of individuals who have an event
(stroke, MI, ESRD, disability, or death), and the costs
associated with each event, in each treatment option.
This simulation continues until the model terminates,
which is when the cohort reach age 65 or dies.
Subsequently, the model can generate, for each treatment
option, the number of people alive at the end of the
simulation, and the quality of life of those
individuals. These outputs can be used to calculate the
additional lives saved and the cost per Quality Adjusted
Life Years (QALYs) gained (See Appendix C) with one
treatment option over the other.

Individuals in the cohort have the flexibility of
moving from one state to another based on transition
probabilities associated with treatment options. The
transition probabilities then dictate the progression of
cohorts through the different paths depending on
severity of events and the individual's age. For
instance, older persons have a higher probability of
death, independent of health. Severity of events,
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whether severe, mild, or fatal, also affects transition
and is calculated based on a fixed proportion.19 For
example, of those who have a stroke, a fixed proportion
of them are assumed to have a severe, fatal, and mild
stroke.

The model simulates the progression paths byfollowing a hypothetical cohort of uninsured who have
M S . The model compares the two treatment options - Early
Treatment versus Late Term Treatment, by calculating the
incremental QALY gained and number of lives saved as the
cohort transition from one state to another. The cohort
is followed until they die or reach age 65, which ever
occurs first. After age 65, it is assumed that they
automatically get absorbed into Medicare system and
hence will be able to get medical attention as and when
needed. However, at the start of simulation, everyone is
assumed to be in the 'well' state, which denotes perfect
health. The Markov cycle is designed as a recurrent
decision tree and hence allows any person who recovers
completely to start in the 'well' state again. For those
who are disabled as a result of an event, or have ESRD,
we assumed that the disease state is not regressive, and
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hence they cannot progress into the 'well' state again.
In this case, the individual will remain in that state
in recurrent cycles until the model terminates. However,
individuals can transition to the death state at any
time.

The cohort is characterized by age since prevalence
of MS increases with age. Also, the incidence rates for
the outcomes increases with age. Age-specific incidence
rates are derived from various sources.17,18 Age-specific
death rates are derived from US 2000 life tables and
adjusted for specific disease conditions and insurance
status. The Late Term Treatment group were treated with
augmented mortality rates since the uninsured have a
higher mortality rate, as proven by many studies.19

Death could occur due to any of the three events,
due to disability, or any other cause. Immediate death
does not incur costs, however, death that occurs after
medical attention incurs costs, and as a result, the
model emphasizes the transition based on severity of
events. Stroke is categorized into fatal, severe, and
mild; MI as fatal or non-fatal. Early Treatment will
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reduce the incidence or delays the progression of
adverse events. The model calculates effectiveness of
one treatment option over the other, based on transition
probabilities and utility of life measures associated
with each treatment option.

H e a lth U t il it ie s
A health state provides information about an
individual's health condition. They play an important
role in the economic appraisal of a treatment option by
indicating the value gained or lost by the individual
for being in a particular state. Since patients are at
different health states, comparisons can be made more
efficiently, if health states are assigned a numerical
value. To accomplish this objective, health utilities
are assigned to health states. Each health state is
given a utility value between zero and one to describe
the health status of the individual. A utility value of
1 indicates perfect health, and zero indicates death.
The utility values used for this study are derived from
two studies. 20,23 A value of 0.5 is assigned for stroke,
0.88 for MI, 0.61 for ESRD, and 0.46 for disability. The
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model uses health utilities to compute the QALYs. QALYs
are commonly used to measure the quality and quantity of
life by taking into account the life expectancy and
quality of remaining life years. Thus, one QALY
represents one year of life spent in perfect health.

T r a n s itio n P r o b a b il itie s
In every cycle, individuals in the cohort may
progress to any of the predetermined health states,
which are estimated by the disease progression design
based on expert opinion and various clinical trials and
models.2'3,6'15'23'25 The transition of the cohort from one
state to another depends on a specific occurrence rate.
Usually, many of the clinical trials and models depict
transition as a percentage of the population in a
particular state. In order to simulate the progression
of the disease in a Markov model, the percentages or
rates have to be converted into probabilities. This is
accomplished by using the Poisson's equation.

[Poisson's

equation: P=l-(eA-rt) where P=probability, r=rate, and
t=time]. Since treatment starting at the onset of the
syndrome will render fewer people in adverse health

14

states, treatment options play an important role in
determining the transition probabilities.

In c id e n c e R a t e s
Incidence rates, like mortality rates are modeled
as a function of age. When the uninsured are treated at
the onset of the syndrome (Early Treatment), the
incidence rates are assumed similar to the general
population. The underlying scenario is that, once the
uninsured are intensively treated on a regular basis,
they no longer assume the risks of the uninsured. Hence,
the estimates used in the analysis for the uninsured who
undergo Early Treatment pertain to an insured
population.

The annual age-specific incidence rate of stroke is
derived from a study by Williams GR,17 which used
nationwide sample of 20% of all inpatient data. MI
incidence rates are obtained from a study by Wolf PA,21
and ESRD incidence rates from the United States Renal
Data System.18 These incidence rates relate to the
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general population and hence are applied to the Early
Treatment cohort. For the Late Term Treatment cohort,
the incidence rates increases considerably as proven by
many studies. The proportion by which it increases is
derived from the results of the Heart Outcomes
Prevention Evaluation (HOPE) Study reported by Heinig
RE22 and The CDC Cost-effectiveness Group.23 For the Late
Term Treatment cohort, the model uses a 44% greater
incidence for stroke, 35% greater incidence of MI, and
50% greater incidence of ESRD. However, treatment of
type 1 and type 2 diabetes is found to reduce ESRD
incidence by 71%.24

The higher incidence rates for Late Term Treatment
cohort is due to the lack of intensive treatment. The
difference in incidence rates is obtained by comparing
conventional treatment to intensive treatment.
Conventional treatment involves patients to control
their diet, exercise, and in some cases, patients are
treated with certain medications. Hence, the real effect
of the Early Treatment option is subdued since the model
assumes that the uninsured with MS help in the reduction
of risk factors, even when not treated. The effect of
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intensive treatment would seem more significant if the
difference in incidence rates were a comparison of Early
Treatment to no treatment at all, which is usually the
condition of the uninsured, who are undiagnosed and
untreated.

M o r t a l it y R a t e s
The all-cause mortality rates for the general
population are derived from the 2000 US Life Table.
These rates were recalculated after eliminating the
death rates due to the four other causes of death
(stroke, MI, ESRD, and disability) that are already
present in the model. The mortality rates were then
corrected for two other effects - multiple risk factors,
and insurance status. The presence of multiple risk
factors has proven to increase overall mortality rates.
Previous studies25'19 have shown that diabetics have up to
2.75 times higher risk of non-cardiovascular mortality
rates compared to non-diabetics. Golan et al26 have used
a standardized mortality ratio of 2.0 for all-cause
deaths in diabetics. We assumed that people with MS have
similar risks as the diabetics, and hence, applied a
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mortality ratio of 2.0 to the life tables to quantify
the additional mortality rates due to the risk factors
of MS. This mortality rate is applied to both treatment
options - Early Treatment and Late Term Treatment. A
study by the Board on Health Care Services,7 showed that
the uninsured, on average, have a 25% higher risk of
mortality compared to the insured population.
Considering this, the excess mortality among the
uninsured is calculated by applying the mortality ratio
of 1.25 to the 2000 US life tables. This mortality rate
is used for individuals undergoing Late Term Treatment
only. The Early Treatment cohort is conceived to be
similar to the insured population, because of their
ability to receive treatment on a regular basis and have
access to needed care.

S e v e r it y

of

Events

In clinical practice, treating an event has
different costs associated with it depending on its
severity. For example, a stroke that causes a person to
become disabled will have a higher treatment cost than a
stroke that will allow the person to get back to perfect
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health. In the case of stroke that causes disability,
considerable expense occurs for a longer period of time.
We therefore apportioned events into different
categories based on severity, which portrays
disproportionate costs. A fixed proportion of the cohort
having an event is expected to have either a mild,
severe, or a fatal event. The fractions for severity of
stroke and MI are derived from a study by Elliot et
al.19 Stroke is characterized into fatal, severe, and
mild. Of the cohort having a stroke, 25% of them have a
severe stroke which may led to long term disability, 25%
are fatal, and 50% are minor stroke. Mild stroke victims
are assumed to revert back to perfect health, and fatal
stroke victims incur no costs since death occurs before
any medical attention is provided. MI is categorized
into fatal or non-fatal. A fixed 35% of the patients are
expected to have a fatal MI.

Health insurance status varies the severity of
events. Being uninsured and hence not receiving
treatment for the risk factors increases the severity of
events. Thus, in the Late Term Treatment group, there is
a higher incidence of fatal events. A number of clinical
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trials have evaluated the effectiveness of treating risk
factors by comparing cohorts who have received
medication versus a placebo. The West of Scotland
Coronary Prevention Study (WOSCOPS) and the Heart
Outcomes Prevention Evaluation (HOPE) study have
indicated that medication reduces stroke mortality and
MI mortality by 19% and 31% respectively. 27,28 These
rates are used as increased event fatality rates for the
Late Term Treatment cohort. The mortality rates for ESRD
are fixed at 27% annually.26 Mortality rates for
disability are derived from the United States Social
Security Administration database.29

Although individuals with ESRD or disability are at
increased risk of having another event such as stroke or
MI, these effects have not been considered in the model,
as the event probabilities in such scenarios have not
been well quantified. As a result, ESRD and disability
are modeled as recurring states, which indicate that a
person with disability or ESRD cannot transition into
other states, and thereby, will continue to be in that
state until the model terminates. As mentioned earlier,
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the model terminates when individuals reach age 65 or
die.

C o sts

of

T r eatm en t

and

C o m p l ic a t io n s

All costs used in the model are derived from
medical literature. Since this population is high risk,
it is assumed that the cohort receives intensive
treatment for any of the risk factors of MS they may
have. Intensive treatment consequently provides better
outcomes and is proven to significantly reduce event
rates. In addition, intensive treatment is more
expensive than conventional treatment, and hence, the
costs and outcome measures of intensive treatment
considered for this study is to quantify the best value
gained in treating uninsured individuals with MS.
Consequently, utility values and disease progression
rates in the Early Treatment cohort assume values that
occur due to intensive treatment.

The cost of intensive treatment of hypertension,
hyperlipedemia, and blood glucose was derived from two
cost-effectiveness studies23,25 that expressed costs in
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1997 and 1995 US dollars respectively. This cost
included annual costs of medication, physician visits,
and the required laboratory tests. Cost of treating the
individual risk factors of MS is pertinent to the Early
Treatment cohort alone, since the Late Term Treatment
group is assumed to get treatment only for an event
occurring as a result of MS. The cost of events depends
on its severity. Treating severe events are more
expensive than treating mild events. The data for costs
of treating events was derived from a study by Elliott
et al.19 All costs were adjusted for inflation based on
the US Bureau of Labor Statistics to represent 2001 US
dollars. The costs of treating risk factors and events
are listed in Table 1.

Table 1: Base Case Parameters

Value

Variable

30

Age
Cost of Disability

$46,327

Cost of ESRD

$44,764

Cost of Fatal MI

$17,998

Cost of Fatal Stroke

$26,710

22

Cost of Mild Stroke

$13,354

Cost of Non-fatal MI

$35,996

Cost of Non-fatal Stroke

$53,459

Cost of Hyperlipidemia Treatment

$1,543

Cost of Diabetes Treatment

$1,157

Cost of Hypertension Treatment

$661

Probability of ESRD

0.00024

Probability of MI

0.00544

Probability of Stroke

0.000716

Probability of ESRD (uninsured)

0.000312

Probability of MI (uninsured)

0.007072

Probability of Stroke (uninsured)

0.001032

Probability of death related to age,
0.001328
gender, and race
Probability of death related to age,
0.0013047
gender, and race (uninsured)

Fatal events do not incur any cost due to the
underlying scenario that fatal (immediate death) events
do not incur costs. However, death occurring after
medical attention incurs cost, and is accounted for in
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the analysis. The cost of treating ESRD is $44,764,
derived from the United States Renal Data System.30

O utco m es
The primary purpose of economic evaluations in
healthcare is to be able to rank interventions based on
outcomes.31 In order to compare the treatment options,
two outcomes measure were chosen to represent the value
gained or lost in choosing one treatment option over the
other. They were - cost/QALY gained, and number of lives
saved. These two outcome measures make it possible to
compare the treatment options as it provides a clear
picture of the lasting health benefits of each treatment
option. Hence, the choice of an outcomes measure is
important as it exclusively represents the results of a
cost-effectiveness study. Cost per QALY gained shows the
additional cost needed to generate one year of perfect
health. 32 The number of lives saved depicts the
additional number of people alive as a result of the
treatment option. Using these outcomes, treatment
options can be compared and prioritized based on its
cost to effectiveness ratios. Hence, it is important to

24

access the monetary value of the outcomes so that policy
makers can decide what options to consider so that it
will yield a greater social benefit. The costs and QALYs
are discounted at 3% annual rate and are expressed in
2001 US dollars.

25

R esults
Ba s e - c a s e
As a base-case scenario, we followed a cohort of
30-year-olds, since the uninsured between the ages 20-34
make up 56% of the low-income uninsured population,33
and 49% of the total uninsured population. Early
Treatment of MS risk factors resulted in a $13,953 per
QALY gained for treatment of hypertension,

$25,929 for

treatment of Diabetes, and $35,331 per QALY gained for
hyperlipidemia treatment. At the end of the simulation
(when the cohort reached age 65), the cumulative medical
cost per person in the Early Treatment cohort was
$10,960, $15,008, and $27,816 higher than the Late Term
Treatment group for hypertension, diabetes, and
hyperlipidemia treatment respectively.

Treating MS in younger people was found to save
more lives compared to treating MS in older people. The
additional number of lives saved with Early Treatment
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for 20 year old cohort was 10.84% and dropped to 5.47%
in the 60 year old cohorts, suggesting that the onset
and treatment of MS at an older age results in a higher
death rate due to co-morbidities. Figure 3 shows the
additional number of lives saved due to Early Treatment
in different age groups. Thus, treating MS at its onset
saves more lives in younger patients than in older
patients.

Figure 3: Cumulative Event Rates by Treatment Groups

Considering this, we can conclude that although the
cost of treatment does not lead to a cost saving (where
the cost-effectiveness ratio, defined as the incremental
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cost cumulative medical costs divided by the change in
QALYs, would have been negative), it helps in extending
the life of individuals. The cost saving is not apparent
as there are more people in the Early Treatment group
who live longer and hence would consume more health
care. This is explored in greater detail in the
sensitivity analysis.

Comparing the two cohorts, we found that there was
a significant decrease in the probability of fatal
stroke, fatal MI, and ESRD in the Early Treatment group
when compared to the Late Term Treatment group. The pvalues for each of those events were 0.056, <.0001, and
0.030 respectively. This analysis was performed using
the Statistic Package for Social Science (SPSS 10.0.1;
SPSS Inc., Chicago, 111). T-tests were performed to
compare the probabilities of events in the two treatment
groups. Figure 4 shows the cumulative incidence of
events (including death) by treatment group over time.
The upper curve represents the event rate of the Early
Treatment and the lower curve represents the cost of
treating the Late Term Treatment cohort. As shown in the
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figure, the event rates are higher in the Late Term
Treatment group as the age of the cohort increases.

Figure 4: Additional number of lives saved with Early
Treatment

S e n s it iv it y A n a l y s is
One-way sensitivity analysis (where only one
parameter is varied at a time) was performed for
treatment of hypertension, diabetes, and hyperlipidemia
by varying parameters such as age, cost, and incidence
rates, and mortality rates of some events. The
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parameters used in the sensitivity analysis are
presented in Table 2.

Table 2: Parameters Used in Sensitivity Analysis

Base-case

Range

Reference

30

20-64

NA

Hypertension

661

266-775

23

Diabetes

1157

1029-1285

25

Hyperlipidemia

1543

600-2100

23, 34

Age
Treatment costs, $:

Increase in event rate for LTT* cohort, %:
Stroke

44

33-69

35, 36

MI

35

22-29

35, 36

ESRD

50

26-71

24, 25

*LTT = Late Term Treatment

Varying Age
As shown in Table 3, the incremental costeffectiveness (the additional cost divided by additional
effectiveness) of Early Treatment over Late Term
Treatment decreases as age increases, but increases for
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the 60 year old cohort. The best cost-effectiveness is
obtained by treating people between ages 50-59. This is
true for treatment of all the three risk factors
(hypertension, diabetes, and hyperlipidemia). It may be
recalled that the additional number of lives saved with
Early Treatment relative to Late Term Treatment
decreases as age of the cohort increases. Tying this
effect of Early Treatment with its incremental costeffectiveness, we can conclude that cost-effectiveness
is higher for younger cohorts, as they tend to live
longer and consequently use more medical care.

Table 3: Incremental Cost-effectiveness of Early Treatment
(Cost/QALY Gained)

Treatment age

Hypertension Diabetes Hyperlipidemia

20

$17,012

$31,115

$42,077

30

$13,953

$25,929

$35,331

40

$10,953

$21,234

$29,226

50

$8,582

$18,215

$25,703

60

$11,684

$27,788

$40,306
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Varying Costs
Using the lowest cost of treatment yielded an
incremental cost-effectiveness of $4,325/QALY gained for
treating hypertension,

$22,840 for diabetes, and

$12,424/QALY for treating hyperlipidemia in a cohort of
30-year-old patients. Using the upper limits for the
treatment costs, the incremental cost-effectiveness was
found to be 16,667/QALY gained for treating
hypertension,

$29,033/QALY gained for treating diabetes,

and $48,795/QALY gained for treating hyperlipidemia.
Although the incremental cost-effectiveness ratio varies
with the treatment cost of risk factors, the results
obtained were within the acceptable range
($40,000/QALY). (See Appendix C) The upper limit of
cost-effectiveness of treating hyperlipidemia
($48,795/QALY), although slightly over the conventional
limit, has been acceptable in many of the federally
mandated projects, such as use of passenger side air
bags (69,000/QALY gained) and intensive neonatal care
($47, 000/QALY) .37
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Varying Event Rates
Varying the event rates in the Late Term Treatment
group, the cost-effectiveness of Early Treatment of
hypertension ranged from 10,656/QALY to $17,587/QALY,
diabetes ranged from 18,464/QALY to 28,126/QALY, and
treatment of hyperlipidemia ranged from 29,329/QALY to
42,792/QALY. This demonstrates that Early Treatment is
more cost-effective if the incidence rates of adverse
events are lowered to a greater extent, compared to the
Late Term Treatment group. This justifies our choice of
intensive treatment of risk factors in the uninsured
population with MS, rather than the conventional
treatment.
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Limitations

The limitations in this study are primarily due to
lack of sufficient data on the combined effects and
costs of all the risk factors of MS. Furthermore, there
are relatively fewer clinical trials performed among the
uninsured, which adds to our limitation in terms of data
and true effects of treatments, as we have extrapolation
the results of the general population to the uninsured.
The effectiveness of not treating uninsured population
was derived from published data of clinical trials,
which used placebo to determine the effect of no
treatment. This naturally undermines our costeffectiveness estimates due to the placebo effect. A
placebo effect is a mysterious positive effect in a
patient's health when treated with placebo. Likewise,
when comparing the two treatment options, the difference
in the incidence rates of events is obtained from a
study comparing moderate treatment and intensive
treatment. Moderate treatment includes diet and drugs,
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which is known to provide some amount of health
benefits. In the model, although we consider the Late
Term Treatment group to have no treatment at all, we
have in fact incorporated the effects of moderate
treatment. Hence the analysis would provide better costeffectiveness ratios if the uninsured in the Late Term
Treatment group were modeled as not having any kind of
moderate care.

Apart from therapies directed at the individual
risk factors of MS, lifestyle changes have also been
commonly recommended for patients with MS to help reduce
adverse outcomes. However, this model takes into account
specifically the clinical costs and effectiveness of
treating MS assuming that patients do need medication to
control their risk factors. The model also assumes that
patients follow treatment regimen and hence we did not
assess the influence of treatment discontinuation or
non-compliance issues. Furthermore, the treatment of MS
is assumed to start at the onset of the syndrome, rather
than at clinical diagnosis. Hence, the model does not
account for the development of clinical complications
before diagnosis and treatment, and assumes that there
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are no other co-morbidities present at the start of the
treatment regimen.

In this model, due to data limitations, we have
assumed that the probability of having an event is
independent of previous events. Realistically,
recurrence rates are higher in people who have already
had an event. The cycle time, being one year, does not
account for recurrent events that occur within a oneyear period. Also, the model does not permit transition
of people who are disabled or have ESRD to any other
state other than death. This assumption was primarily
due to lack of data on the transition probability and
utility of life measures for those who were already
disabled or have ESRD and had another event.

In modeling the risk factors of MS, we have
approximated the costs and effects of treating
dyslipidemia with costs and effects of treating
hyperlipidemia. Hyperglycemia is evaluate as diabetes
mellitus, as a study by Alexander TM et al38
demonstrated that 86% of diabetic patients, age 50 and
over, have M S .
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Incidence and progression of risk factors of MS are
modeled to be a function of age. However, they are also
dependent on gender, race, and family history. For
example, African American women are found to have 57%
higher prevalence of MS compared to men. We have not
incorporated the effects of some of these demographic
differences in the analysis.

In terms of determining the cost of treating the
individual risk factors of MS, costs of medication,
physician visits, and tests for each of the risk factors
are incorporated in the model. It can be argued that
since people with MS may have more than one of these
risk factors, physician visits may be common to all the
risk factors they may have. In the model, physician
visits is associated with the risk factor and not the
individual. This may have led to double counting of cost
of treatment of risk factors, which again underestimates
the cost-effective analysis results.

The cost of each treating risk factors and the
events are derived from studies that used the 1996 or
1997 dollars. These cost, although have been adjusted
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for inflation to represent 2001 dollars, it does not
account for changes in treatment criteria, or the
improvement in technology that helps deliver more
economical care. In addition, health care inflation is
found to be higher than the normal inflation rate, but
this has not been taken into account in this analysis.
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Conclusions

MS in the uninsured is an issue that is not
sufficiently investigated, and as its prevalence is
increasing, more research in this area would help to
better understand the syndrome and its consequences. The
risk factors of MS, especially hypertension and
diabetes, are of serious concern as a large number of
those having the syndrome are unaware of its presence.
Hence, a greater value lies in increasing awareness of
MS risk factors. It is found that 31.6% of hypertensives
and 34.6% diabetics are unaware of their condition.39

The cost-effectiveness results demonstrate that the
cost/QALY gained in treating MS risk factors in the
uninsured lie within the conventionally accepted
thresholds. Also, our sensitivity analysis supports our
initial results, thereby suggesting that our model was
sufficiently robust. Our results showed that treating MS

39

in people between ages 50-59 is most cost-effective, but
the number of lives saved is the highest for younger
cohort.
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Appendices
A p p e n d ix A

- T he M e ta b o lic S y n d r o m e

According to the NCEP definition, person having
three or more of the following criteria is clinicallydiagnosed as having MS:
- Abdominal obesity: waist circumference >102 cm
in men and >88 cm in women;
- Hypertriglyceridemia: >150 mg/dL (1. 69 mmol/L);
- Low high-density lipoprotein (HDL) cholesterol:
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL
(1.29 mmol/L) in women;
- High blood pressure: >130/85 mm Hg;
- High fasting glucose: >110 mg/dL (>6.1 mmol/L).
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A p p e n d ix B

- H e a lth In su r a n c e

The United States is the only industrialized county
in the world without universal health coverage. In 2002,
there were more than 43.6 million people1 (15.2% of the
population) who were without any form of health
coverage. The concept of health insurance emerged in the
early 20th century and employers used it to attract
workers with the fact that it would protect workers
against unforeseen costs of medical care, and would also
help them receive preventive care so that they stay
healthy longer which would in turn increase
productivity.2 Today, majority of the workers are
privately insured through their employers. However, many
small businesses do not offer health insurance coverage
to its employees. Hence, the majority of the uninsured
tend to be workers with low income. In 1965, when
Medicare and Medicaid were introduced, the intent was to
provide insurance to the elderly and the indigent.

1 U .S .Department of Commerce, Economics and Statistics
Administration. U.S. CENSUS BUREAU. Health Insurance Coverage in
the United States: 2002. Issued September 2003. Available at:
h t t p :// w w w .c e n s u s .gov/prod/2 0 03pubs/p6 0-2 2 3 .pdf

2 Paul Starr. The Social Transformation of American Medicine. Basic
Books, New York NY; 1982.
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Medicare helps to cover the elderly, and Medicaid helps
to cover the indigent and the disabled. Many poor people
do not qualify for the Medicaid program since the
criteria are very stringent, so much so, that the
poorest of people (incomes below 200% of the federal
poverty level) are refused coverage and only the
severely disabled get coverage.3 There are options for
people to buy their own plans. Individual plans usually
have high premiums or offer limited benefits, which does
not make it appealing to the low-income people. Hence,
the low-income people are left with no choice but
continue being uninsured.

The consequences of being uninsured are tremendous.
A report by The Kaiser Commission on Medicaid and the
Uninsured3 shows that the uninsured receive less
preventive care, forgo needed care (because of cost),
and hence lead a sicker life and have higher mortality
rates. Although it has been proven that the insured use

3 Jack Hadley. Sicker and Poorer - The Consequences of Being
Uninsured: A Review of the Research on the Relationship between
Health Insurance, Medical Care Use, Health, Work, and Income.
Medical Care Research and Review. June 2003; Vol. 60, No. 2,
Supplement. Available at: http://www.kff.org/content/2003/4115/
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more medical care,4 (as the uninsured tend to avoid
medical care) the uninsured accumulate financial costs,
which are passed on to the society. Since the uninsured
usually use the emergency department visits for needed
care, the cost of care increases dramatically, as ER
visits are the most expensive form of care. It is found
that the uninsured use emergency department visits four
times more than the insured. On average, it was
estimated that the uninsured pay only about a quarter of
their medical cost out-of-pocket. Incidentally, these
rates are much higher than what an insured person pays,
since the co-pays through health insurance is lower than
what a person would have to pay without insurance.
However, about 35% of the total medical cost in treating
the uninsured is reported as uncompensated.

There are some striking facts about the improvement
in health and consequently the rise in the cost of
treating the uninsured. It is estimated that if the

4 Jack Hadley and John Holahan. Covering the Uninsured: How Much
Would It Cost?. Health Affairs (Web Exclusive). June 4, 2003.
Available at:
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uninsured had access to better care, it would help them
increase their earnings by 10-30%. It would also
decrease hospitalization rates and mortality rates
significantly. Hence, one policy option suggested by
many researchers is to extend Medicare benefits to the
uninsured. This is the premise of our study since we are
proposing the allocation of public funds to treat the
uninsured to reduce adverse outcomes on a long-term
basis. Furthermore, the uncompensated costs of treating
the uninsured will reduce substantially. Since the
uninsured will be diagnosed at an early stage, which
will help decrease progression of diseases, the number
of emergency department visits will consequently
decrease. When consistent preventive care and access to
medication continues, expensive and unexpected
procedures can be avoided, which in the long run, will
be beneficial. The current approach of not providing
preventive care for the uninsured, and hence having a
cost saving, is deemed to be 'shortsighted',5 as the

http://www.healthaffairs.org/WebExclusives/Hadley_Web_Excl_060403.h
tm
5 Marieke D. Schoen et. al. Impact of the Cost of Prescription
Drugs on Clinical Outcomes in Indigent Patients With Heart Disease.
Pharmacotherapy. 2001; 21(12): 1455-1463
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society will have to bear the expenses of delayed
medical care and poor disease control, which are more
expensive to treat.
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A p p e n d ix C -

qalys

Health economists and health professionals at large
have found it very difficult and also have been hesitant
in measuring the value of an individual's health in
monetary terms. The argument here is whether to value a
rich person's life differently than a poor person's
life. This consequently becomes more of an ethical issue
rather than an economics issue. Unless there is some
level ground to measure health benefits, there is always
going to be a discrepancy in the way health care
interventions and developments are valued. So far, the
quality-adjusted life-year (QALY) has been widely
accepted in the health community as it assesses both the
quality and quantity of life rather than having a dollar
amount on life. Critics of the cost per QALY method
argue that treatment for acute conditions may not be
eligible since they might not show a net societal
benefit, which results in inequality, since this method
would suggest accepting programs that benefit more
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people than programs that benefit only a few.6

The

other method commonly used in such scenarios is known as
the 'Willingness to Pay'

(WTP), which directly assigns a

value to health in monetary terms and does not identify
an upper limit to health benefits. The limitation of
this method is that it cannot be used to measure many
different health scenarios without surveying individuals
for each of those scenarios.

Quality-adjusted life-year accounts for
differential impacts of one intervention over another
both in terms of quality and quantity of life gained.
The rationale for using both quality and quantity of
life is because they are two basic components that
interventions are designed to enhance. Mathematically, a
QALY is derived by multiplying life expectancy (a
quantity measure) and health utility (a quality measure)
of the remaining life-years. Although the quantity of
life, or life expectancy, is easily measured, quality of
life calls for more calculations. There are a number of

6 Mohan V. Bala; Gary A. Zarkin. Are QALYs an Appropriate Measure
for Valuing Morbidity in Acute Diseases? Health Econ. 2000; 9: 177180
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ways to measure the quality of life, or health utilities
- standard gamble, time trade-off, and visual analog
scales are the ones that are commonly used methods. In
the visual analog scales method, patients rate their
health status on a scale of zero to one, one being
perfect health. In time trade off method, patients
indicate the number of years of perfect health that is
equivalent to the number of years in a particular health
state. In standard gamble method, patients propose their
willingness to accept the risk of death in order to
shift from a specific health state to perfect health.
Hence utility value of zero represents death and one
represents perfect health. However, some health states
may be considered worse than death and may carry a
negative score.

Hence, QALYs provide a uniform ground for comparing
different health care interventions in terms of
maximizing the benefits of patients. Using cost per QALY
identifies whether the cost for the intervention exceeds
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the value gained.7 Prioritizing different interventions
can be done by comparing the cost per QALY of all the
interventions and choosing the one that has a lower cost
per QALY. The commonly accepted threshold is $40,000 per
QALY.7 The justification for this amount is due to the
fact that dialysis costs $40,000 per QALY, and Medicare
covers the costs of dialysis patients. Since Medicare is
a federally funded program and consists of -taxpayers'
contributions, it is assumed that society believes that
a $40,000 per QALY threshold is beneficial. However,
there have been cases where interventions that exceed
this threshold have also been chosen. In essence, QALYs
provide a tool for policymakers when resource allocation
decisions need to be made between competing medical
services.

7 Gold, MR, Siegel JE, Russell LB and Weinstein, MC. (eds.) Costeffectiveness in Health and Medicine. New York: Oxford University
Press. 1996
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A p p e n d ix D

- M ark ov M o d e ls , S e n s itiv ity A n a ly s is , an d DATA

4.0
Economic evaluation tools are becoming increasingly
common in clinical decision making to help measure
outcomes of various clinical strategies. Since cost is a
determining factor in most health care interventions,
cost-effective analysis using decision models has become
popular as it provides a simplified structure to assist
in determining the most effective option. Markov models,
also known as state transition models, are commonly used
for such analyses. Markov models are particularly
helpful for several reasons - it helps in building the
analytical structure representing the important events
that repeat over time, synthesizes effectiveness data
and compares it to the costs associated with it, and
calculates the desired output. A Markov model consists
of a finite set of states, which represents the
different health conditions that a member of the cohort
can possibly assume. At any given time, a cohort member
can assume only one possible state. Each state is
associated with a utility value, which helps in
determining or describing the health outcomes of a
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particular state. Each state is linked to one another
depending on the probability of their occurrence. The
probability of occurrence is also called transition
probabilities, which help in transitioning the members
of the cohort among possible states during a single
cycle. A cycle is defined as a specified interval of
time (that is clinically meaningful) during which a
transition occurs. At the beginning of the simulation,
it is often assumed that the entire cohort starts in the
same state. There are three types of states in a Markov
model - absorbing state, temporary state, and transient
states. Absorbing states are essential to help terminate
the simulation. It typically determines the end state
that is defined by the study. Usually, the death or
disability is an absorbing state in cases where the
model spans the entire life of a patient. On the other
hand, if the cycle length is short, typically for models
studying short-term impact, there may be other
termination states. A temporary state is a state that
models a short-term event, which typically does not last
for more than one cycle. A tunnel state is a set of
temporary states such that one state occurs after
another in a predefined fashion, and lasts for more than
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one cycle. Transition probabilities can be constant or
time-dependent. The incidence of stroke can be dependent
on age and hence time-dependent, whereas, transition
from disability to death may be constant.

The modeling technique used to simulate the
progression of the metabolic syndrome is performed by
cohort simulation using DATA 4.0 software. Cohort
simulation is the most intuitive representation of the
Markov process, where a cohort of patients transition
through the model simultaneously. DATA uses a graphic
decision tree representation of a Markov model (also
known as 'Markov-cycle tree') and integrates the
principle elements for the simulation, which include,
transition probabilities, cycle length, and utility
value and/or cost of being in a health state. The cohort
cycles through the different states in the model, until
they reach a termination criterion specified by the
design of the simulation. One assumption of the Markov
model, also known as the Markovian property, is that the
current health states are independent of previous health
states. In other words, patients' history cannot
determine their transition from one health state to
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another; their transition will be determined by the
transition probability associated with the state.
However, if previous histories have to be implemented in
the model, a special subset has to be created for the
cohort with a particular utility.

DATA has a built in discounting function that
discounts both costs and utilities. Discounting is
essential because it takes into account the present
value of future costs and benefits. It is based on the
fact that a given amount of resources is less valuable
in the future than at present. Hence a Markov cycle tree
combines the simplicity of a decision tree and realistic
representation of clinical problems.

DATA also helps in performing sensitivity analysis.
When initial values are assigned to variables, the most
plausible values are taken into account. Usually, there
is always a possibility of a range of values that may
fit the unknown quantities. If the range of assumptions
is accounted for in the model, it increases the
robustness of a model. Hence, the practical reason for a
sensitivity analysis is to obtain a range of values that
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would help in reducing the uncertainty associated with
the assigning initial values (base case) to variables.
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Data
Tables used in the Markov Model:

m
H*

Age, Gender, and Race Related Mortality Rates
LTT*
Age
0.001025
0.000938
20
21
0.001139
0.00108
22
0.001215
0.001175
0.001241
0.001208
23
24
0.001231
0.001195
0.001149
25
0.001199
0.001191
0.001139
26
0.001144
27
0.001195
28
0.001223
0.001179
0.001244
29
0.001275
30
0.001329
0.001305
0.001403
0.001397
31
32
0.001532
0.001511
0.001717
33
0.001659
34
0.001833
0.001935
0.002024
35
0.001936
0.002266
36
0.00213
0.002541
37
0.00235
0.002602
38
0.002856
0.003211
39
0.002886
0.003171
0.003558
40
41
0.003958
0.003491
42
0.003839
0.004393
0.004881
43
0.004229
44
0.005426
0.004665
0.00448
45
0.004246
0.005155
46
0.004786
47
0.005352
0.005863
0.00592
0.006573
48
0.006494
0.00729
49
0.004932
50
0.005276
0.005774
51
0.00595
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52
53
54
55
56
57
58
59
60
61
62
63
64
65

0.006704
0.007772
0.009012
0.009209
0.010847
0.012632
0.014507
0.016482
0.016108
0.018613
0.021295
0.024108
0.027063
0.025441

0.006694
0.007548
0.00854
0.008975
0.010285
0.011713
0.013213
0.014793
0.015051
0.017055
0.019201
0.021451
0.023815
0.023535

*ET = Early Treatment, LT = Late Term Treatment

Stroke Mortality Rates
Probability
Age
3.88E-05
20
35
0.000115
45
0.000366
55
0.001028
65
0.002535

Stroke Incidence Rates
Probability
Age
20
0.00031
0.00092
35
45
0.00293
0.00822
55
65
0.02028

Stroke Incidence Rates in Uninsured
Probability
Age
20
0.000446
35
0.001325
45
0.004219
0.011837
55
65
0.029203

Stroke Mortality Rates in Uninsured
Age
Probability
20
5.58E-05
0.000166
35
0.000527
45
55
0.00148
65
0.00365
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Ml Mortality Rates
Probability
Age
45
0.00133
50
0.003115
60
0.00455
65
0.005705

Ml Incidence Rates
Probability
Age
45
0.0076
0.0178
50
0.026
60
65
0.0326

Ml Incidence Rates in Uninsured
Probability
Age
45
0.00988
0.02314
50
60
0.0338
0.04238
65

Ml Mortality Rates in Uninsured
Age
Probability
0.001729
45
50
0.00405
60
0.005915
0.007417
65

ESRD Incidence Rates
Age
Probability
25
0.000178
0.000242
30
0.000292
35
40
0.000412
45
0.000636
0.000954
50
0.001412
55
0.001952
60
0.002524
65

ESRD Mortality Rates
Age
Probability
25
0.00002403
0.00003267
30
0.00003942
35
0.00005562
40
0.00008586
45
0.00012879
50
0.00019062
55
0.00026352
60
0.00034074
65

ESRD Incidence Rates in Uninsured
Age
Probability
0.00022962
25
30
0.00031218
35
0.00037668
40
0.00053148
0.00082044
45
50
0.00123066
55
0.00182148
60
0.00251808
0.00325596
65

ESRD Mortality Rates in Uninsured
Age
Probability
0.000036045
25
0.000049005
30
35
0.00005913
0.00008343
40
0.00012879
45
0.000193185
50
0.00028593
55
60
0.00039528
65
0.00051111
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